Immunosuppression

Chapter

Keywords

Rejection Calcineurin inhibitors Steroids Antimetabolites Polyclonal antibodies Induction therapy 

References

  1. 1.
    Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658–63.Google Scholar
  2. 2.
    Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28(3):638–45.CrossRefPubMedGoogle Scholar
  3. 3.
    Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373–83.e1.CrossRefPubMedGoogle Scholar
  4. 4.
    Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg. 1999;5(4 Suppl 1):S30–6.PubMedGoogle Scholar
  5. 5.
    Beaudreuil S, Samuel D, Rouas-Freiss N, Durrbach A. New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? Transpl Immunol. 2007;17(2):98–107.CrossRefPubMedGoogle Scholar
  6. 6.
    Wiesner RH, Ludwig J, Krom RA, Hay JE, van Hoek B. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment. Mayo Clin Proc. 1993;68(1):69–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Demetris AJ, Murase N, Lee RG, Randhawa P, Zeevi A, Pham S, Duquesnoy R, Fung JJ, Starzl T. Chronic Rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Annals of Transolantation 1997;2(2):27–44.Google Scholar
  8. 8.
    Johnston JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, et al. Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J Biol Chem. 1995;270(48):28527–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Wells AD. Cell-cycle regulation of T-cell responses—novel approaches to the control of alloimmunity. Immunol Rev. 2003;196:25–36.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim EY, Lee EN, Lee J, Park HJ, Chang CY, Jung DY, et al. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation. Exp Mol Med. 2006;38(3):284–94.CrossRefPubMedGoogle Scholar
  11. 11.
    Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016;77(11):1063–70.CrossRefPubMedGoogle Scholar
  12. 12.
    O’Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplant. 2016;16(2):603–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Demetris AJ, Bellamy C, Hubscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16:2816–35.CrossRefPubMedGoogle Scholar
  14. 14.
    Stites E, Le Quintrec M, Thurman JM. The complement system and antibody-mediated transplant rejection. J Immunol. 2015;195(12):5525–31.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8(11):670–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. 1976. Agents Actions. 1994;43(3–4):179–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut. 2009;58(3):452–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987;19(5 Suppl 6):4–8.PubMedGoogle Scholar
  19. 19.
    Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23–46.CrossRefPubMedGoogle Scholar
  20. 20.
    Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant. 2009;2009:701464.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003;18(Suppl 1):i12–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol. 1996;16(6):536–47.PubMedGoogle Scholar
  23. 23.
    Velidedeoglu E, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, et al. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc. 2002;34(8):3315–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–40.CrossRefGoogle Scholar
  25. 25.
    Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens. 1991;4(5 Pt 1):468–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, et al. Neurologic complications of FK 506. Transplant Proc. 1991;23(6):3175–8.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Reznik VM, Jones KL, Durham BL, Mendoza SA. Changes in facial appearance during cyclosporin treatment. Lancet. 1987;1(8547):1405–7.CrossRefPubMedGoogle Scholar
  28. 28.
    U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med. 1994;331(17):1110–5.CrossRefGoogle Scholar
  29. 29.
    O’Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360(9340):1119–25.CrossRefPubMedGoogle Scholar
  30. 30.
    Pichlmayr R, Winkler M, Neuhaus P, McMaster P, Calne R, Otto G, et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. Transplant Proc. 1997;29(5):2499–502.CrossRefPubMedGoogle Scholar
  31. 31.
    Bottiger Y, Undre NA, Sawe J, Stevenson PJ, Ericzon BG. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc. 2002;34(5):1544–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2012;12(10):2797–814.CrossRefGoogle Scholar
  33. 33.
    Merli M, Di Menna S, Giusto M, Giannelli V, Lucidi C, Loria I, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. Transplant Proc. 2010;42(4):1322–4.CrossRefGoogle Scholar
  34. 34.
    Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl. 2003;9(6):587–95.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46(2):149–54.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Klupp J, Bechstein WO, Platz KP, Keck H, Lemmens HP, Knoop M, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation—first results. Transplant Int. 1997;10(3):223–8.CrossRefGoogle Scholar
  37. 37.
    Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transpl. 1996;10(1 Pt 2):77–84.Google Scholar
  38. 38.
    Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429–55.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sollinger HW. Mycophenolates in transplantation. Clin Transpl. 2004;18(5):485–92.CrossRefGoogle Scholar
  40. 40.
    Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation. 2003;76(1):130–6.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001;7(5):442–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet. 2001;357(9256):609–10.CrossRefPubMedGoogle Scholar
  43. 43.
    Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85(12):1675–85.CrossRefPubMedGoogle Scholar
  44. 44.
    Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3 Suppl):7S–14S.CrossRefPubMedGoogle Scholar
  45. 45.
    Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant. 2004;4(1):137–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Fung J, Marcos A. Rapamycin: friend, foe, or misunderstood? Liver Transpl. 2003;9(5):469–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14(5):633–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl. 2001;7(6):473–84.CrossRefPubMedGoogle Scholar
  49. 49.
    Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003;75(5):657–62.CrossRefPubMedGoogle Scholar
  50. 50.
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005;11(9):1064–72.CrossRefPubMedGoogle Scholar
  51. 51.
    Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996;51(5):865–94.CrossRefPubMedGoogle Scholar
  52. 52.
    Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;4:CD005161.Google Scholar
  53. 53.
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334(13):815–20.CrossRefGoogle Scholar
  54. 54.
    Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998;28(5):756–63.CrossRefPubMedGoogle Scholar
  55. 55.
    Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679–87.CrossRefPubMedGoogle Scholar
  56. 56.
    Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant. 2010;10(3):590–601.CrossRefPubMedGoogle Scholar
  57. 57.
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003;38(5):1282–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6(8):1922–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(10):1254–61.CrossRefPubMedGoogle Scholar
  60. 60.
    Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12(12):1813–24.CrossRefPubMedGoogle Scholar
  61. 61.
    Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68(2):253–6.CrossRefPubMedGoogle Scholar
  62. 62.
    McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron. 1990;55(2):121–8.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Fan PY. Renal replacement therapy after liver transplantation. Transplantation. 2005;80(3):425–6. author replyCrossRefPubMedGoogle Scholar
  64. 64.
    Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transpl Int. 2013;26(2):109–18.CrossRefPubMedGoogle Scholar
  65. 65.
    Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31(4):461–76.CrossRefPubMedGoogle Scholar
  66. 66.
    Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl. 2016;22(5):627–34.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol. 1990;10(1):113–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Adams DH, Neuberger JM. Treatment of acute rejection. Semin Liver Dis. 1992;12(1):80–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Kim PT, Demetris AJ, O’Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the ‘two-hit hypothesis’. Curr Opin Organ Transplant. 2016;21(2):209–18.CrossRefPubMedGoogle Scholar
  71. 71.
    Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev. 2009;23(1):34–46.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Enoka Gonsalkorala
    • 1
  • Daphne Hotho
    • 1
  • Kosh Agarwal
    • 1
  1. 1.Institute of Liver StudiesKings College HospitalLondonUK

Personalised recommendations